Prostate Cancer Highlights from ASCO 2021 with Pedro Barata

This year, at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021, experts came together virtually to present and discuss the latest findings in oncology. In this podcast, Pedro Barata, MD, MSc Tulane University School of Medicine, New Orleans, LA, discusses highlights from the meeting. He focuses on the results from four Phase III trials assessing various therapies for the treatment of prostate cancer. Dr Barata begins with VISION (NCT03511664), examining the addition of lutetium-177 to standard of care treatment in progressive metastatic prostate cancer, followed by PEACE-1 (NCT01957436), investigating abiraterone and prednisone ± radiotherapy for hormone-naïve metastatic patients. He continues by highlighting Peace III (NCT02194842), a trial investigating enzalutamide and radium-223 combination therapy in asymptomatic or mildly symptomatic castration-resistance patients and concludes by talking about the SWOG S1216 study (NCT01809691), examining androgen deprivation therapy plus TAK-700 in patients with hormone-sensitive prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021.